Piracetam & MAOIs
Piracetam is a nootropic drug that is often used to enhance cognitive function, memory, and learning.
Piracetam is a member of the 2-oxopyrrolidine family of compounds. It has a pyrrolidone nucleus with an acetamide side chain. The precise mechanisms by which Piracetam works are not fully understood, but it is believed to modulate the activity of several neurotransmitter systems in the brain, including the cholinergic, glutamatergic, and GABAergic systems.
One proposed mechanism of action is that Piracetam enhances the activity of acetylcholine, a neurotransmitter involved in memory and learning processes. Piracetam diminishes hippocampal acetylcholine levels in rats without significantly modifying choline levels, indicating that it may act by accelerating the release of acetylcholine and other neurotransmitters. Alterations in density and function of several neurotransmitter receptors occur in animal and human brain during the normal aging process. Chronic treatment of ages mice with Piracetam restores deficit of muscarinic cholinergic receptor density and function.
Piracetam may also modulate the activity of glutamate, the brain's primary excitatory neurotransmitter. By increasing the activity of NMDA receptors. Additionally, Piracetam has been shown to increase blood flow and oxygen consumption in the brain, which may further enhance cognitive function by improving the delivery of nutrients and oxygen to brain cells.
Overall, Piracetam appears to have a multifaceted mechanism of action, affecting several neurotransmitter systems and physiological processes in the brain. While the precise mechanisms by which Piracetam works are not fully understood, its ability to enhance cognitive function and memory has been demonstrated in numerous clinical studies.
Monoamine oxidase inhibitors (MAOIs) are a class of drugs used primarily to treat depression and other mental health conditions. MAOIs work by inhibiting the activity of the enzyme monoamine oxidase (MAO), which is responsible for breaking down certain neurotransmitters in the brain, including serotonin, dopamine, and norepinephrine.
In the brain, these neurotransmitters play important roles in regulating mood, emotions, and other cognitive functions. By inhibiting the activity of MAO, MAOIs increase the levels of these neurotransmitters in the brain, which can help to alleviate symptoms of depression and other mental health conditions.
There are two types of MAO in the brain, MAO-A and MAO-B, and MAOIs can target one or both of these enzymes. MAO-A is primarily responsible for breaking down serotonin and norepinephrine, while MAO-B is primarily responsible for breaking down dopamine. Some MAOIs target both MAO-A and MAO-B, while others target only one of these enzymes.
The mechanisms of interaction between Piracetam and MAOIs are not fully understood, but the combination could potentially lead to difficult-to-predict conditions.
On the one hand, we have not met reliable data on any consequences of the combined use of Piracetam and MAOIs. Annotations and instructions for medicines also do not note pronounced negative interactions between these substances. Also the possibility of changing the pharmacokinetics of Piracetam under the influence of other drugs is low, because 90% of the drug is excreted unchanged by the kidneys. In general, metabolic interactions of Piracetam with other drugs are unlikely.
On the other hand, several old studies note that Piracetam, in addition to all of the above, shows activity in relation to MAO:
- During a 30-day period, administering Piracetam at a high doses resulted in a notable 20% reduction in the activity of MAO when tested in vivo. In vitro experiments showed that Piracetam had an inhibitory effect on MAO too.
- Piracetam activated MAO in both the striatum and hypothalamus in a rat's brain, and activation of MAO-B in both regions, but with a marked inhibitory impact on MAO-A in the striatum.
We see that these are quite diverse results that were obtained more than 30 years ago. It seems unjustified to take them into account against the background of the past time, but it would be wrong not to mention these facts.
So, we have vague potential paths for negative interactions between substances in combination, and a complete lack of up-to-date and reliable data on such.
Nevertheless, Piracetam clearly has a multi-vector and systemic effect on the brain. Despite its weak ability to interact in general, Piracetam can enhance the effect of psychostimulants and the central effects of thyroid hormones. In combination with neuroleptics, it increases the severity of extrapyramidal disorders. Therefore, it is impossible to declare that its combination with IMAOs is completely safe.
In light of these considerations, we strongly recommend a meaningful approach and caution to this combination.
Last edited by a moderator: